Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.

about

Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.

Item

http://www.wikidata.org/entity/Q52725862

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@en

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@nl

type

Item

label

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@en

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@nl

prefLabel

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@en

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@nl

P1476

Antitumor activity of nimotuzu ...... ancer cell line A549 in vitro.

@en

P2093

Duanduan Yin

http://www.w3.org/2001/XMLSchema#string

Jiandong Wu

http://www.w3.org/2001/XMLSchema#string

Jiangman Zhao

http://www.w3.org/2001/XMLSchema#string

Lei Xue

http://www.w3.org/2001/XMLSchema#string

Lixin Yao

http://www.w3.org/2001/XMLSchema#string

Qianyi Zhang

http://www.w3.org/2001/XMLSchema#string

Shu Dong

http://www.w3.org/2001/XMLSchema#string

Wenwen Zhou

http://www.w3.org/2001/XMLSchema#string

Xiaoyu Wang

http://www.w3.org/2001/XMLSchema#string

Yanhong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

Targeting the epidermal growth factor receptor in non-small cell lung cancer.

Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.

S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial

P304

5280-5284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.7923

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29552167

http://www.w3.org/2001/XMLSchema#string

P932

5840536

http://www.w3.org/2001/XMLSchema#string